Investigators
Top 5 Investigators in 2023
Dr Voon Pei Jye
Dr. Voon Pei Jye is an accomplished physician with extensive experience in oncology and clinical research. Currently serving as the Head of Department for the Radiotherapy and Oncology Department at Sarawak General Hospital in Kuching, he holds an M.D. from Universiti Malaysia Sarawak and MRCP from the Royal College of Physician, United Kingdom. Dr. Voon also holds a Master of Medicine and Advanced Specialist Training in Medical Oncology from the National University of Singapore and National Cancer Institute Singapore, as well as a Clinical Research Fellowship in Phase 1 Drug Development Program from Princess Margaret Cancer Centre, University Health Network, Toronto. Dr. Voon is an active clinical researcher and is currently overseeing numerous ongoing clinical trials. His research contributions have been recognized with numerous awards and honors. Additionally, he has published multiple manuscripts and presented abstracts and posters at various conferences. Dr. Voon is one of the scientific committee members of Asia Pacific Oncology Drug Development Consortium and also ATLAS Board. He is also a member of several professional committees and societies, including the Malaysian Oncological Society, European Society of Medical Oncology (ESMO), and American Society of Clinical Oncology (ASCO).
Dr Chew Lee Ping
Dr Chew Lee Ping is an accomplished consultant haematologist with over a decade of experience practicing at Sarawak General Hospital in Kuching. She obtained her medical degree from Universiti Sains Malaysia in 1999 and went on to attain MRCP(UK) in 2003. Dr Chew pursued her speciality training in Haematology at Hospital Kuala Lumpur and Peter MacCallum Cancer Centre in Melbourne for a year, honing her skills and expertise in the field.
Dr Chew’s primary focus is on malignant and non-malignant blood disorders. She has made significant contributions to the field as an active participating investigator in many multicentre clinical trials, particularly in lymphoma treatment and red blood cell disorders. Currently, she is holding 7 clinical trials as the Principal Investigator. Her dedication and commitment to advancing medical knowledge and improving patient outcomes have earned her the respect and admiration of her colleagues and patients alike.
Dr Eng Jie Yi
Dr Eng Jie Yi is a Clinical Oncologist at Sarawak General Hospital. She obtained her medical degree from National University Malaysia in 2011 and Master of Clinical Oncology, University Malaya in 2021. She is actively involved in international clinical trials as primary investigator focusing on upper gastrointestinal tract, pancreatobiliary malignancy and skin malignancy. She has special interest in hereditary cancer syndrome and advocating for the preservation of patient’s quality of life in cancer care.
Dr Ngu Ming Ruey
Dr. Ngu Ming Ruey is a dedicated clinical oncologist with a strong foundation in both clinical practice and academic research. She holds a Master of Clinical Oncology from the University of Malaya and obtained fellowship status with the Royal College of Radiology, United Kingdom.
She specializes in the comprehensive management of cancer patients, employing advanced therapies and treatments to optimize patient outcomes. Dr Ngu is an active clinical researcher and currently involved in multiple oncology clinical trials in Sarawak General Hospital as principal investigator and sub-investigator.
Dr Ngu is also a member of professional societies including Malaysian Oncological Society (MOS), Malaysia Medical Association, Academy of Medicine Malaysia, European Society of
Medical Oncology (ESMO), Royal College of Radiologists UK.
Dr Chua Hock Hin
Dr. Chua Hock Hin is an infectious disease physician who is also an infection prevention and control practitioner in Sarawak General Hospital. His vision is to improve infectious disease services through clinical research. His area of clinical research in infectious disease involves diseases such as HIV, rabies, influenza, COVID 19 vaccine and therapeutics, melioidosis and antimicrobial resistance.
He has completed 18 Clinical Trials and currently he has 4 ongoing Clinical Trials.
